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Background: Many women try to stop smoking in pregnancy but fail. One difficulty is that there is insufficient
evidence that medications for smoking cessation are effective and safe in pregnancy and thus many women prefer
to avoid these. Physical activity (PA) interventions may assist cessation; however, trials examining these
interventions have been too small to detect or exclude plausible beneficial effects. The London Exercise And
Pregnant smokers (LEAP) trial is investigating whether a PA intervention is effective and cost-effective when used
for smoking cessation by pregnant women, and will be the largest study of its kind to date.
Methods/design: The LEAP study is a pragmatic, multi-center, two-arm, randomized, controlled trial that will target
pregnant women who smoke at least one cigarette a day (and at least five cigarettes a day before pregnancy), and
are between 10 and 24 weeks pregnant. Eligible patients are individually randomized to either usual care (that is,
behavioral support for smoking cessation) or usual care plus a intervention (entailing supervised exercise on a
treadmill plus PA consultations). The primary outcome of the trial is self-reported and biochemically validated
continuous abstinence from smoking between a specified quit date and the end of pregnancy. The secondary
outcomes, measured at 1 and 4 weeks after the quit date, and at the end of pregnancy and 6 months after
childbirth, are PA levels, depression, self-confidence, and cigarette withdrawal symptoms. Smoking status will also
be self-reported at 6 months after childbirth. In addition, perinatal measures will be collected, including antenatal
complications, duration of labor, mode of delivery, and birth and placental weight. Outcomes will be analyzed on
an intention-to-treat basis, and logistic regression models used to compare treatment effects on the primary
outcome.
Discussion: This trial will assess whether a PA intervention is effective when used for smoking cessation during
pregnancy.
Trial registration: ISRCTN48600346
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asthma, attention deficit disorder, learning difficulties,
and obesity [1-6]. Smoking also presents immediate risks
for the mother, including placental abruption [7], as well
as the longer-term risks reported for smokers in general.
Smoking in pregnancy is a major public health problem
in high-income countries; in the USA, 14% of pregnant
women smoke throughout their pregnancy [8]; in the
UK, 12% of pregnant women smoke [9], although a fig-
ure of 40% has been reported in deprived areas [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of their pregnancy, and of these, around two thirds re-
start smoking post-natally [11]. The most effective
smoking-cessation therapy in non-pregnant smokers is a
combination of behavioral support plus nicotine replace-
ment therapy (NRT), bupropion, or varenicline [12-14].
However, the safety and efficacy of NRT during pregnancy
is not yet known [15], thus many pregnant women are re-
luctant to use NRT [16], and other smoking-cessation
medications are contraindicated during pregnancy [17].
Behavioral support can increase smoking cessation rates
in pregnancy by around 6% [18], and there is a need to
identify other non-pharmacological interventions that are
effective for smoking cessation during pregnancy.
Pharmaceutical aids for quitting are thought to work
mainly through reducing cigarette cravings [14], and
there is good evidence that PA moderates these cravings,
therefore PA interventions have the potential to aid
smoking cessation. A recent systematic review consid-
ered the evidence for PA aiding cessation for smokers in
general [19]. Most of the 15 randomized controlled trials
(RCTs) reviewed were insufficiently powered to detect a
meaningful difference between the treatment groups,
with seven of the trials having fewer than 25 participants
in each treatment arm. Six adequately powered trials
compared a group receiving a PA intervention as an ad-
junct to behavioral support with a group receiving be-
havioral support alone. Three of these studies showed
significantly higher smoking abstinence rates in a physic-
ally active group versus a control group at end of treat-
ment [20-22]. One of these studies also showed a benefit
on abstinence for exercise versus control at the 3-month
follow-up, and a benefit for exercise of borderline sig-
nificance (relative risk (RR) = 2.19, p = 0.05) at the
12-month follow-up [20]. A further study showed sig-
nificantly higher abstinence rates for the exercise group
compared with control group at the 3-month follow-up,
but not at the end of treatment or at the 12-month
follow-up [23]. The latter study also found that those
with higher levels of exercise adherence were signifi-
cantly more likely to achieve abstinence at the end of
treatment. The study with the most intensive PA inter-
vention (sessions of supervised vigorous intensity exer-
cise three times per week) showed the strongest effect
on abstinence rates [20]. The other studies entailed PA
interventions that were insufficiently intensive to ensure
the desired levels of PA. It was concluded that PA levels
need to be raised to at least 110 minutes a week to aid
long-term abstinence, and supervised exercise sessions
on two or more days per week are probably necessary to
achieve this aim.
Physical activity could also aid smoking cessation dur-
ing pregnancy. Moderate-intensity PA is recommended
during pregnancy [24,25], and may represent an attractiveaid to cessation for pregnant smokers who are reluctant
to use NRT [16] or who wish to use it as an adjunct to
NRT, and who fear post-cessation weight gain or who are
concerned about weight and muscle-tone issues during
post-partum [26]. Pregnant smokers have been shown to
express interest in using PA to help them quit [27], and
we have conducted two pilot studies to assess the feasibil-
ity of using PA for smoking cessation during pregnancy
[28]. In the first study, 10 women recruited from ante-
natal clinics attended eight once-weekly sessions combin-
ing individual behavioral support for smoking cessation
with 30 minutes of brisk walking and PA consultations.
All the women requested a more extensive PA program;
despite this, five women achieved continuous abstinence
(validated by carbon monoxide (CO) levels) to the end of
pregnancy. In the second pilot, a more intensive interven-
tion entailed 22 women receiving 9 weeks of individual
smoking cessation support, plus 15 sessions of supervised
exercise (brisk treadmill walk or stationary cycling) and
PA consultations. Three women maintained continuous
(CO validated) abstinence to the end of pregnancy,
attending on average 11 of the 14 exercise sessions. All
the abstinent women achieved the target of 110 minutes
of PA each week. Combining both pilots, 25% of the
women (8/32) sustained continuous abstinence to the end
of pregnancy. Our pilot work suggests that it is feasible to
provide a PA intervention, combining supervised exercise
and PA consultations, as an aid to smoking cessation dur-
ing pregnancy.
Aim
The aim of this paper is to describe the protocol for an
RCT designed to evaluate an intervention for increasing
PA as an aid for smoking cessation during pregnancy.
Methods
Study design
The London Exercise And Pregnant smokers (LEAP)
study is a pragmatic two-arm RCT into which pregnant
women who smoke are recruited from antenatal clinics
in National Health Service (NHS) trust hospitals (see
Figure 1 for a flowchart of the LEAP study design).
The study will compare the effectiveness on smoking
cessation of individual behavioral support for smoking
cessation plus a PA intervention, relative to individual
behavioral support alone at the end of pregnancy.
Ethics approval
Ethical approval for the study was given by Wandsworth
Research Ethics Committee and research governance ap-
proval was obtained from each of the 13 hospital trusts
recruiting to the study. Each participant is to provide
written informed consent.
Assessed for eligibility 
Pregnant women recorded as 




Primary outcome of continuous smoking 
abstinence assessed at end of pregnancy
Those lost to follow-up (n=approximately 43)
will be counted as having resumed smoking.
Allocated to exercise intervention (n=433):
Six weekly sessions of smoking cessation 
support, 14 supervised exercise sessions over 
eight weeks, plus nine physical activity 
consultations over eight weeks.
Primary outcome of continuous smoking 
abstinence assessed at end of pregnancy
Those lost to follow-up (n=approximately 43)
will be counted as having resumed smoking.
Allocated to ‘Usual care’ intervention (n=433):








Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the London Exercise And Pregnant smokers (LEAP)
trial design.
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Exercise trials for smoking cessation often target those
who report smoking 5 to 10 or more cigarettes a day.
However, many pregnant smokers under-report the
number of cigarettes they smoke [29], therefore, women
are eligible if they report currently smoking at least one
cigarette a day and report smoking at least five cigarettes
a day before pregnancy. Participants are eligible if they
are aged 16 to 50 years, 10–24 weeks pregnant (subject
to confirmation that they have had a scan to show a vi-
able pregnancy), prepared to quit smoking 1 week after
enrolment, and confirm that they are able to walk con-
tinuously for at least 15 minutes. Women are excluded if
they are unable to complete self-administered question-
naires in English (because of lack of resources for trans-
lators) or if they report having any medical condition
that might be exacerbated by exercise. There are no
documented contraindications to moderate-intensity ex-
ercise, but if the women have been advised by their doc-
tor or midwife not to take exercise during pregnancy, if
they have any complications during their pregnancy, or
if they have any cautions for taking exercise [24,30], a
consultant obstetrician and gynecologist at their hospital
will be consulted to check that it is safe for them to par-
ticipate. Participants joining the trial are monitored ateach treatment session for cautions to exercise and for
adverse events. Those with drug or alcohol dependence
will also be excluded as the intervention described here
is not sufficiently comprehensive to address the pro-
blems of women who have drug or alcohol dependence.
Although NRT is licensed for use in pregnancy, there
is mixed evidence on its effectiveness in helping women
quit smoking during pregnancy [15], and the most
robust trial to date has found no evidence that it is ef-
fective [31]. In addition, many pregnant smokers prefer
not to use NRT [16]. Allowing participants in the trial to
use NRT might create confounding, and therefore,
women who indicate that they wish to use NRT at the
outset will be excluded. Our pilot work shows that preg-
nant smokers are willing to attempt to quit without
using NRT as part of a research study [28]. Following
the guidelines [17], those women who are unable to stop
smoking after their quit day, and who express a clear
wish to receive NRT, will be prescribed NRT by their
general practitioner (GP). Use of NRT will be monitored
throughout the intervention period with the following
questions:
 Have you used any nicotine replacement therapy
(NRT) this week?
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 How many days, approximately, have you used NRT
in the past week?.
In addition, at the end of pregnancy follow-up partici-
pants will be asked the following questions:
 Besides the help we have given you, have you
received any face-to-face support to stop smoking
during your pregnancy?
 If yes, approximately how many sessions have you
attended?.
The subjects’ GPs, midwives, and obstetricians will be
informed of their patient’s participation in the trial.
Sample size
A Cochrane review suggests that approximately 9% of
women who are still smoking at the time of their first
antenatal visit will stop smoking with usual care
through to the end of their pregnancy, and a further
6% will stop as a result of a smoking cessation program
using individual behavioral support [18]. Thus, in our
control group we expect a smoking cessation rate of
around 15% at the end of pregnancy. Combining our
pilot studies, 25% (8/32) of participants in the treat-
ment group sustained continuous smoking abstinence
to the end of pregnancy. Therefore, in the trial we con-
servatively estimate an abstinence rate of 23% at the
end of pregnancy in the treatment group, which would
be similar to the effect shown for NRT with non-
pregnant smokers [14]. We aim to recruit 433 women
to each arm to detect the above absolute difference
(8%) in smoking cessation rates between the groups at
end of pregnancy with a two-sided significance level of
5% and power of 83%. This calculation is based on a χ2
test with Yates correction.
Recruitment
Recruitment for the trial is taking place over a 44-month
period, between April 2009 and November 2012, in 13
NHS hospital trusts in London and the south-east of
England. During the trial, smoking status for all preg-
nant women will be recorded in the hospital computer-
ized patient administration system at the first antenatal
booking visit, which is typically at 9–14 weeks of gesta-
tion. At this time, the midwife will inform all women
recorded as smokers that it is the hospital’s policy to
telephone them to offer smoking-cessation support. This
support would usually be offered by the primary care
trust (PCT) stop-smoking advisor, but during the period
of recruitment to the study, a trial researcher will tele-
phone the women. Those who are interested in receiving
help with quitting will be invited to join the trial or bereferred to the PCT. Information for the first antenatal
appointment will be accompanied by a flyer inviting
women who smoke to join the study. Those women
expressing interest in volunteering will be screened for
eligibility by a telephone interview, and eligible women
will be sent a patient information sheet. As an incentive
for recruitment, and to increase attendance rates, all
women attending at least 80% of their treatment sessions
will be entered into an annual lottery with three annual
prizes of £100 shopping vouchers.
Randomization
At the first visit, eligible and consenting patients will be
individually randomized to one of the two treatment
arms based on a computer-generated pseudo-random
code using random permuted blocks of randomly varying
size, created by the Nottingham University Clinical Trials
Unit (CTU) and held on a secure server. The
randomization will be stratified by center, and block
randomization will be used to ensure good balance be-
tween intervention and control within centers and thus
minimize the risk of any ‘center effect’ influencing the
outcome. Access to the sequence will be confined to the
CTU data manager. Allocation to treatment arms will be
in the ratio 1:1, and investigators will access the treat-
ment allocation for each participant by means of a re-
mote, secure internet-based randomization system
developed and maintained by the CTU. Allocation will
be concealed from the patient until they have completed
all baseline assessments. The sequence of treatment allo-
cations will be concealed until interventions have all
been assigned and recruitment, data collection, and la-
boratory analyses are complete.
Interventions
The interventions (Table 1, Table 2) follow CONSORT
guidelines for non-pharmacologic interventions [32,33].
The same therapists, including research midwives,
nurses, and psychologists, will deliver both the control
and exercise interventions. Two therapists operate at
three of the recruitment sites, and the remaining 10 sites
have been assigned a single therapist. Delivery of the
interventions will be standardized by training and by
the therapists following the supplied manuals (see
Additional file 1, see Additional file 2). The initial com-
petence of the therapists will be assessed by the trial
manager observing role-play scenarios during training.
The fidelity of the interventions will be checked during
the first 6 months by regular observations (at least five
intervention sessions) by the trial manager. All sessions
will be face-to-face and one-to-one, and will be delivered
in a private room at the hospital or in a community
health center. Social cognitive (learning) theory [34] is
the theoretical basis for the interventions. This theory
Table 1 Behavior change techniques (BCTs) used in the smoking-cessation consultations in this study
Week Session number Session content BCTs used
(Michie categoriesa)
1 Session 1 (1 week before quit day) Explain the treatment, including timing of quit RC4, BS4
Measure expired CO and explain purpose RC3
Assess and discuss current and past smoking behavior RI1
Identify reasons for wanting and not wanting to quit BM9
Assess current motivation/confidence for quitting R12
Discuss past attempts at quitting R13
Prepare for the quit attempt BM6, BS3
Discuss use of social support A2
Advise on reducing smoking cues BS8
Advise subject to note the times when they are likely to lapse BS6
Facilitate relapse prevention planning and coping BS2
Identify barriers to quitting and address these barriers BS1
Emphasize choice (for example, when the participants
take their final smoke)
RD2
Provide information about the consequences of smoking
during pregnancy
BM1, RC5
Explain about quitting abruptly, rather than cutting down BM10
For all sessions:
Allow time for questions RC2
Summarize RC9
Use reflective listening RC7
Elicit participant’s views RC8
Build a general rapport RC1
Give praise for progress BM7
Tailor the interactions RD1
2 Session 2 (quit day) Look for reasons why the woman is a good prospect BM2, BM3
Explain about cigarette withdrawal symptoms and strategies
for dealing with them
RC6
Identify barriers to quitting and address these barriers BS1
Advise on avoiding social cues for smoking BS11
Advise on changing routine BS7
Advise on conserving mental resources BS10
Set graded tasks (for example, take 1 hour/day at a time) BS9
3 Session 3 (1 week after quit day) Check smoking status BS5
Assess withdrawal symptoms R14
Reassure about the norms for these symptoms RC10, BM5
Advise subject to monitor when they want to smoke BS6
Assess CO and give feedback about whether reading has reduced BM11, BM3
Discuss planning and coping strategies to prevent relapse BS2
If they, have relapsed ask them to commit to a new quit date BM6
Advise about use of NRT A1
Liaise with PCT about obtaining NRT A3
Encourage subject to see themselves as a non-smoker BM8
Remind them of lottery prize for attending all sessions BM7
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Table 1 Behavior change techniques (BCTs) used in the smoking-cessation consultations in this study (Continued)
4 Session 4 (2 weeks after quit day) onwards Assess CO BM11
Check smoking status BS5
If they are struggling offer further support from PCT A5
Discuss relapse prevention planning and coping strategies
for after birth
BS2, BM8
Emphasize importance of not having a single puff BM6
If subject has relapsed, set a new quit date, and review use of NRT A4
CO, carbon monoxide; PCT, primary care trust; NRT, nicotine replacement therapy.
aMichie categories are defined as follows.
Specific focus on the target behavior (B) and maximizing motivation (M). BM1: provide information on consequences of smoking and smoking cessation. BM2: boost
motivation and self-efficacy. BM3: Provide feedback on current behavior. BM5: provide normative information about others’ behavior and experiences: BM6:
prompt commitment from the client there and then. BM7: Provide rewards contingent on effort or progress. BM8: strengthen ex-smoker identity. BM9: identify
reasons for wanting and not wanting to stop smoking. BM10: explain the importance of abrupt cessation. BM11: measure CO levels.
Maximizing self-regulatory capacity and skill (BS). BS1: facilitate barrier identification and problem-solving. BS2: facilitate relapse-prevention and coping. BS3:
facilitate action-planning/develop treatment plan. BS4: facilitate goal-setting. BS5: prompt review of goals. BS6: prompt self-recording. BS7: advise on changing
routine. BS8: advise on environmental restructuring. BS9: set graded tasks. BS10: advise on conserving mental resources. BS11: advise on avoiding social cues for
smoking.
Promoting adjuvant activities (A). A1: advise on stop-smoking medication. A2: advise on/facilitate use of social support. A3: adopt appropriate local procedures to
enable clients to obtain free medication. A4: ask about experiences of stop-smoking medication that the smoker is using. A5: give options for additional and later
support.
General aspects of interaction focusing on delivery of the intervention (RD). RD1: tailor interactions appropriately. RD2: emphasize choice.
General aspects of interaction focusing on information gathering (RI). RI1: assess current and past smoking behavior. RI2: assess current readiness and ability to quit.
RI3: assess history of quit attempts. RI4: assess withdrawal symptoms.
General aspects of interaction focusing on general communication (RC). RC1: build general rapport. RC2: elicit and answer questions. RC3: explain the purpose of CO
monitoring. RC4: explain expectations regarding treatment program: RC5: offer/direct toward appropriate written materials. RC6: provide information on
withdrawal symptoms. RC7: use reflective listening. RC8: elicit client views. RC9: summarize information/confirm client decisions. RC10: provide reassurance.
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ample, self-efficacy to quit smoking or increase PA) and
social/environmental factors (for example, social sup-
port) on health behavior change. For each session that
they attend, the women are paid £7 for their travel
expenses.
Control group
Those in the control group will receive behavioral sup-
port for smoking cessation, which is generally provided
via the NHS Stop Smoking Services to pregnant women
as part of ‘usual care’. By extracting the elements of the
intervention from written manuals and materials pro-
vided by the program (see Additional file 1), the contents
of the intervention have been classified in accordance
with the taxonomy of behavior-change techniques
(BCTs) described by Michie and colleagues, and used in
individual behavioral support for smoking cessation [35]
(Table 1). The researchers delivering the intervention will
be trained to NHS Centre for Smoking Cessation and
Training standards during a 2-day course [36]. Partici-
pants will receive six once-weekly sessions of behavioral
support, each session lasting for approximately 20 min-
utes. This begins 1 week before the quit date and ends 4
weeks after that date. A pregnancy-specific smoking ces-
sation program is used [17], the contents of which are
described in Table 1. The intervention incorporates all 43
BCTs for smoking cessation defined by Michie and col-
leagues [35], except for the BCT ‘provide rewards contin-
gent on successfully stopping smoking’, although rewardswill be offered to increase compliance (see Table 3). Con-
tinuing support will be offered to women who fail to quit
or relapse to smoking.
Treatment group
In addition to behavioral support for smoking cessation,
those in the PA group will receive a PA intervention,
combining PA consultations and supervised exercise. By
extracting the elements of the PA consultation from
written manuals and materials provided by the PA pro-
gram (see Additional file 2; see Additional file 3), the
contents of the PA consultation have been classified in
accordance with the taxonomy by Michie and colleagues
of behavioral change techniques used to help people
change their PA behaviors [37]. The researchers deliver-
ing the PA intervention will be trained during a 2-day
course. There are 14 sessions of supervised exercise,
twice a week during the first 6 weeks of the intervention,
and then once a week for 2 weeks. During the first 6
weeks, when the smoking-cessation support is provided,
one of the exercise sessions will be combined with the
smoking-cessation support. Following a familiarization
session at the first visit, participants will be advised to
aim for 30 minutes of continuous treadmill walking dur-
ing each session. Following the guidelines [38],
moderate-intensity exercise will be prescribed according
to age and current activity levels, and monitored using a
polar heart-rate monitor. Intensity of exercise will also
be guided by the rating of perceived exertion (RPE) [39]
(‘fairly light’ to ‘somewhat hard’) and by the ‘talk test’,
Table 2 Behavior change techniques (BCTs) used in the physical activity (PA) consultations
Week Session number Session content BCTs used
(Michie categoriesa)
1 Session 1
(one week before quit day)
Review current PA and discuss PA benefits 1, 2
Explain and demonstrate use of treadmill and pedometer 7, 21, 22, 26
Check PA confidence levels using scaling questions 16
All sessions:
Agree PA goals 10
Provide weekly PA and step-count diaries 16
Allow time for questions, summarize, use reflective listening,
elicit participant’s views, build a general rapport
Give praise for effort and for achieving PA goals 12, 13
1 Session 2 Review PA goals and effect of PA on cravings 7, 9, 10
Complete cost-benefit analysis for increasing PA 2
Identify PA barriers and problem solve 8
Explain and demonstrate exercises in booklet 21, 22, 26
Provide information on places to exercise 20
Discuss time management and exercise habits 23, 38
Plan social support 29
Provide weekly PA diary and step-count diary 16
2 Session 3 (quit day) Review PA goals, set heart-rate targets on treadmill 10
Identify PA barriers and problem solve 8
Provide weekly PA diary and step-count diary 16
Check PA confidence levels with scaling questions 8
3 Session 4 (one week after quit day)
onwards
Review PA goals, set heart-rate targets on treadmill 10
Plan for relapse prevention/coping 35
Review exercises in booklet 21, 22, 26
Review social support 29
Use imagery to encourage identity as an ‘exerciser’ 34
Provide weekly PA diary and step-count diary 16
Reminder that sessions reduce to once a week for the last 2 weeks
of the program
27
Check PA confidence levels with scaling questions 8
aMichie categories are defined as follows.
1) Provide information on consequences of behavior in general. 2) Provide information on consequences of behavior to the individual. 7) Action-planning. 8)
Barrier identification/problem-solving. 9) Set graded tasks. 10) Prompt review of behavioral goals. 12) Prompt rewards contingent on effort or progress towards
behavior. 13) Provide rewards contingent on successful behavior. 16) Prompt self-monitoring of behavior. 20) Provide information on where and when to perform
the behavior. 21) Provide instruction on how to perform the behavior. 22) Model/demonstrate the behavior. 23) Teach subject to use prompts/cues. 26) Prompt
practice. 27) Use of follow-up prompts. 29) Plan social support/social change. 34) Prompt use of imagery. 35) Relapse-prevention/coping planning. 38) Time
management.
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the woman cannot hold a conversation.
Twice a week for the first week and then once a week
(alternating with smoking cessation support), prior to
using the treadmill, the women will receive around 20
minutes of PA consultation (total of nine sessions),
aimed at increasing PA undertaken outside the super-
vised sessions (Table 2). The intervention incorporates
19 of 40 BCTs for increasing PA as defined by Michie
et al. [37]. The researcher and participant will work
through a booklet incorporating the behavior-changetechniques (see Additional file 1). The participants will
be encouraged to view exercise as a self-control strategy
for reducing cigarette cravings and withdrawal [40], and
to maintain any increases in PA after their pregnancy.
Following recommendations for pregnancy [24,25], the
women will be advised to be active for continuous peri-
ods of at least 10 minutes at a time, progressing towards
accumulating 30 minutes of activity on at least 5 days of
the week. The emphasis will be on brisk walking, which
is popular among pregnant smokers [41]. As a further
option, a home-based antenatal exercise DVD and
Table 3 Financial incentives offered to trial participants
Incentive occasion Maximum financial incentive, GBP
Exercise group Control group
Annual lottery with three prizes
of £100a for attending at least
80% of treatment sessions
100 100






£10a for follow-up at end
of pregnancy
10 10
£10a for follow-up at 6 months
after birth
10 10
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given a pedometer (Digi-Walker SW-200; Great Per-
formance Ltd, London, UK) for monitoring their daily
steps. Pedometers have been shown to increase activity
levels in women [42], and are acceptable during preg-
nancy [43] and among pregnant smokers [28]. Partici-
pants will be asked to log their daily steps, with the
therapist calculating a 10% increment every 2 weeks,
gradually progressing towards 10,000 steps a day [44].
Baseline data collection
At baseline, demographic characteristics will be recorded,
including age, marital status, number of children, highest
educational qualification, ethnicity, occupation, weeks of
gestation, and history of premature births. Smoking his-
tory will also be recorded, including cigarettes smoked per
day (now and before pregnancy), urge to smoke [45,46],
tobacco withdrawal symptoms [45,46], and Fagerström
Test for Nicotine Dependence score [47], as well as the
partner's smoking status. Depression will be assessed with
the 10-item Edinburgh Postnatal Depression Scale (EPDS)
[48]. Physical activity levels in the previous week will be
assessed for both groups using the 7-day Physical Activity
Interview [49]. The woman’s confidence about taking up




The primary outcome is self-reported continuous abstin-
ence from smoking from the quit date through to the
end of pregnancy, validated by either exhaled CO or sal-
ivary cotinine levels. This outcome is dichotomous (that
is, abstinent or not abstinent). Our definition of continu-
ous abstinence allows a total of five cigarettes after the
quit day [52,53]. Expired CO levels will be assessedweekly up to 4 weeks after the quit day and at end of
pregnancy using a CO monitor (Smokerlyzer; Bedfont
Scientific Ltd, Maidstone, Kent, UK) with a cut-off of <8
ppm [54]. Saliva cotinine levels will be measured at 4
weeks after the quit day and at the end of pregnancy
(cut-off level <10 ng/ml) [55]. The aim is to follow-up
the woman within 2 weeks of the birth; however, the
end-of-pregnancy assessment will be considered valid if
recorded between week 36 of pregnancy and 10 weeks
after the birth. If a woman’s report of abstinence is dis-
confirmed by either her CO or cotinine level, she will be
considered as having resumed smoking. All the data will
be entered on to an online database held on a secure
internet server at the CTU at Nottingham University.
Secondary outcomes
Continuous smoking abstinence will also be assessed at
4 weeks after the quit day and 6 months after the birth.
In addition, we will assess continuous smoking abstin-
ence with a stricter criteria whereby no cigarettes are
allowed after the quit day, at 4 weeks after the quit date,
and at the end of pregnancy. Again, self-reports of
smoking abstinence will be validated by expired CO and
cotinine measurements. Self-reports of smoking status at
6 months after the birth will be reported via telephone
and will not be biochemically validated. As an incentive,
women who complete the follow-up sessions at the end
of pregnancy and at 6 months after the birth will be
given a £10 shopping voucher for each of these follow-
ups. Table 3 summarizes the various financial incentives
offered to the participants.
Many women report that, rather than stopping smok-
ing, they reduce their smoking during pregnancy [56,57],
and there is some evidence to suggest that a reduction
in smoking of 50% or more is associated with increased
infant birth weight [58]. Therefore, levels of smoking re-
duction will be assessed for those women who relapse.
Other secondary outcome measures are: changes in urge
to smoke, tobacco withdrawal symptoms, and confi-
dence in stopping smoking and in maintaining regular
PA. We will also assess changes in depression between
baseline, end of pregnancy and 6 months after the birth,
as well as changes in maternal weight between baseline,
4 weeks after the quit date, and end of pregnancy.
Further self-reports of PA levels (by 7-day recall) will
be collected at weeks 1, 4, and 6 after the quit date and
at both follow-ups (that is, end of pregnancy and 6
months after birth). To objectively validate self-reported
PA levels, 10% of participants in both the treatment
group and the control group will wear an accelerometer
(GT1M; Actigraph, Pensacola, FL, USA) for seven con-
tinuous days during the fourth week after the quit date.
Those who record at least 5 days of Actigraph data will
be compensated with a payment of £25 shopping
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able and valid during pregnancy [59-61]. Duration of
treadmill exercise will be recorded, along with attend-
ance rates at behavioral support and exercise sessions.
The following perinatal measures will be extracted
from patient’s hospital records: (i) antenatal complica-
tions, including any admissions and the reasons for the
admissions, (ii) gestation at onset/induction of labor
(and indication for induction where appropriate), (iii)
duration of labor and mode of delivery, (iv) Apgar scores
of infants, and where available acid–base status of
infants, and rates of transfer to the neonatal intensive-
care unit, and (v) birth weight and placental weight.
Cost-effectiveness
From a health-service perspective, we will examine the
cost-effectiveness of smoking -cessation support plus ex-
ercise relative to smoking-cessation support alone. We
will document resources consumed that are related to
each intervention. Relevant resources include: cost of
personnel, materials, space, equipment, and administra-
tive overheads. Data collection methods include: (i)
accounting for staff time using time and effort reports,
(ii) accounting for computer time, mailing, and program
costs using an accounting system that has been created
to facilitate real-time aggregation of these costs, (iii) and
using interviews with staff to determine the amount of
time they devote to tasks related to the program. The
benefits of smoking cessation in pregnancy will be mod-
eled and not measured. Long-term cessation leads to
long-term benefits to the mother, which must be dis-
counted appropriately. In ‘normal quitters’ who sustain
abstinence for about 6 months, meta-analyses show that
half will relapse, while half will become lifetime abstai-
ners and enjoy these benefits [62,63]. Based on this, we
might expect that most women who stop smoking in
pregnancy, usually for at least 6 months, would maintain
lifetime abstinence. However, a much higher proportion
of women who stop smoking return to it after pregnancy
than would be expected in these models, diminishing
the benefits to the woman herself from smoking cessa-
tion. However, the benefits of smoking cessation in preg-
nancy also extend to the fetus, which will be less likely
to be born pre-term [18]. This leads to reduced NHS
costs and a lower likelihood of complications, such as
cerebral palsy and similar health problems. Avoidance of
these latter health problems leads to gains in quality-
adjusted life years for the baby that must also be
included in the utility measure of the decision analytic
model. Thus we will use an existing method that has
been used for cost-effectiveness modeling for the Na-
tional Institute for Clinical Excellence (NICE), updating
utility estimates to include the benefits to the fetus. The
evidence for this model in measuring the benefits to thefetus and child will be derived from a systematic review of
the effects of smoking cessation in pregnancy on the con-
sequences for the fetus and child that is currently being
conducted by a team at the University of Nottingham, led
by Professor Tim Coleman (co-investigator). The analysis
will allow us to calculate incremental cost-effectiveness
ratios for smoking cessation support plus exercise com-
pared with smoking cessation support alone in terms of
cost of treatments per smoker who quits. We will also be
able to examine ratios for subgroups; for example, accord-
ing to nicotine dependence or age at baseline.Statistical analysis
We will conduct a descriptive comparison of the base-
line characteristics of the two treatment groups. Analysis
will be on an intention-to-treat (ITT) basis. Participants
who, for any reason, have missing outcome data on the
primary outcome or any secondary smoking outcomes,
will be assumed to have resumed smoking [55]. Our pri-
mary outcome measure, continuous abstinence from
smoking from quit date to end of pregnancy, will be
compared between treatment groups using logistic re-
gression, adjusted for recruitment center only, with stat-
istical significance determined by the likelihood-ratio
test and with the estimate of effect given as the odds
ratio and 95% confidence interval. Our primary analysis
will not adjust for any further variables because effect
estimates can be sensitive to decisions concerning what
variables should be adjusted for and how these are speci-
fied. However, we will conduct secondary analyses
adjusting for the following variables that are predicted to
be related to the outcome: education, nicotine depend-
ence, age, and depression. We will analyze other binary
smoking outcomes in a similar way.
We will compare secondary outcomes, including urge
to smoke, withdrawal symptoms, self-confidence, and
PA, in the first week of abstinence, and the same vari-
ables plus maternal gestation weight and depression,
over subsequent time points, using mixed effects model-
ing to allow for repeated measures, with adjustment for
center. To deal with non-normally distributed variables
we will use transformations to normality, residual boot-
strapping, or dichotomizing. Differences between groups
in perinatal outcomes, including birth weight, gestation,
mode of delivery, and complications, will be analyzed by
linear or logistic regression, with adjustment for center.
For fetal outcomes, the primary analysis will be of
singleton births and we will carry out a sensitivity ana-
lysis including multiple births, allowing for the cluster-
ing of outcomes. If we observe differences between the
two groups in use of NRT, or use of behavioral support
outside of the intervention sessions, then we will con-
duct a sensitivity analysis to examine the effect of
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variables.
We will determine the quantity and distributions of
missing data. We will carry out a complete case analysis,
and we will compare this with an analysis using multiple
imputation to deal with missing values, which assumes
data are missing at random, describing any differences
in terms of the biases in the data. The exception is
smoking outcomes, where those with missing data will
be assumed to have resumed smoking [55].
If the intervention is effective, we will use mediation
analysis to examine whether there is evidence that the
change in PA levels is the likely causal factor in deter-
mining smoking abstinence. We will examine the associ-
ation between treatment group and change in PA levels,
and the association between level of PA and abstinence.
Finally, we will include level of PA in a logistic regres-
sion model of the association between treatment group
and abstinence, with mediation assessed using MacKin-
non’s causal steps criteria [64].
Changes to methods since trial enrollment began
Since trial enrollment began on 1 April 2009, the follow-
ing important changes to the methods have been made.
1) For the follow-up at end of pregnancy, the valid
period for assessment was originally defined as 38
weeks gestation to 2 weeks after the birth. Because
there were a number of women who could not be
contacted to be followed up during this time frame,
the valid period was extended to 36 weeks gestation
to 4 weeks after the birth (approved by the research
ethics committee on 18 May 2010). However,
because there were still a few women being followed
up later than 4 weeks after the birth, the valid period
was further revised to 36 weeks gestation to 10
weeks after the birth (approved 31 Jan 2012). The
aim remains to attempt to follow-up as many
women as possible within 2 weeks of the birth.
2) To give the women an incentive to complete the
follow-ups at end of pregnancy and 6 months after
the birth, all women who complete these follow-ups
will be given a £10 shopping voucher for each of the
follow-up sessions attended (approved 18 May 2010).
3) Originally, to be eligible women had to report
smoking at least 10 cigarettes a day before their
pregnancy. We found that a good number of women
reported smoking five to nine cigarettes a day at this
time. Therefore, we extended the eligibility criteria to
include women smoking at least five cigarettes a day
before pregnancy (approved 15 September 2010).
These women are still likely to be dependent on
smoking, as there is evidence that women who say
they were smoking five to nine cigarettes beforepregnancy are back to smoking 14 cigarettes a day at
18 months post-partum [65].
4) Initially, women had to be between 12 and 24 weeks'
gestation to be eligible for the trial. However, since
the trial began, most of the hospital trusts began
offering earlier antenatal booking appointments
(before 12 weeks gestation), and because we wished
to recruit the women as early as possible in
pregnancy, we revised this to 10 to 24 weeks
gestation (approved 31 Jan 2012).
Discussion
Because NHS Stop Smoking Services provide individual
behavioral support to pregnant women as a standard
treatment, we will be testing an intervention that could
be readily introduced into current NHS practice and
might be expected to cost less per patient than conven-
tional treatments, such as NRT. This study has been
designed to address many of the limitations highlighted
in previous research examining PA as an aid for smoking
cessation [15], by including both supervised exercise and
PA consultations, being adequately powered, using a re-
mote randomization system to protect concealment of
allocation, and adopting an ITT approach to the analysis.
If found to be effective, physical activity could be an im-
portant alternative or adjunctive treatment for smoking
cessation during pregnancy, particularly for women who
prefer non-pharmacological interventions. Currently,
however, little is known about the mechanisms that
might mediate any therapeutic effects of PA on smoking
cessation [15]. There are a number of hypothesized bio-
logical and psychosocial mechanisms, but it is likely that
an effective PA intervention would rely on multiple
mechanisms. Future research might identify which par-
ticular mechanisms, and any interactions between them,
are most important, and determine the optimum type,
intensity, and duration of PA required to produce a
therapeutic effect.
Current study status
The LEAP trial began recruiting patients in April 2009,
and recruitment will close in November 2012. Data col-
lection for the primary outcome is due to be completed
in July 2013. As of October 2nd 2012, 768 women have
been recruited.
Additional files
Additional file 1: Therapist manual for delivering smoking
cessation intervention.
Additional file 2: Therapist manual for delivering physical activity
intervention.
Additional file 3: Participant’s handbook for physical activity
intervention.
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